9. Altimmune Inc. (NASDAQ:ALT)
Altimmune, Inc. (NASDAQ: ALT) remains connected to the weight-loss revolution through pemvidutide, a dual GLP-1 and glucagon receptor agonist that previously generated encouraging weight-loss and body-composition data. However, the company has increasingly concentrated its development strategy on liver diseases, including metabolic dysfunction-associated steatohepatitis, alcohol-associated liver disease and alcohol-use disorder. That shift makes Altimmune, Inc. (NASDAQ: ALT) a less direct obesity play than some companies ranked above it, but it could also provide a differentiated route into the broader metabolic-disease market.
The scientific case centers on the balanced activation of GLP-1 and glucagon receptors. GLP-1 activity may reduce appetite and food intake, while glucagon activation could increase energy expenditure and help reduce liver fat. This combination is particularly relevant for people whose obesity is accompanied by fatty-liver disease, inflammation and metabolic dysfunction. The opportunity is not simply to help patients lose pounds; it is to determine whether the same medicine can improve the health of the liver while supporting favorable changes in body composition.
The major concern is that Altimmune, Inc. (NASDAQ: ALT) must compete against much larger companies with deeper financial resources, extensive commercial networks and late-stage metabolic pipelines. The stock’s depressed valuation reflects uncertainty surrounding development strategy, financing and pemvidutide’s eventual commercial positioning. Yet that lower valuation could also create considerable upside if future MASH studies confirm a meaningful benefit and management secures a credible pharmaceutical partner. Altimmune, Inc. (NASDAQ: ALT) belongs on the list because the obesity market is evolving beyond headline weight-loss percentages toward treatments that address the liver, cardiovascular system and other consequences of metabolic disease.
Click next to see the following stock...
